The DuraSite 2 was designed to develop topically delivered ocular drugs with enhanced tissue penetration. The patent will protect the technology’s delivery system and drugs formulated until 2029.
More Articles on Ophthalmology:
Femtosecond Laser Technology May Provide Alternative to Corneal Keratoplasty
Cataract Surgery Improve Vision in Retinitis Pigmentosa Sufferers, Study Says
Atlantic Eye Center in New Jersey Turns 25
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
